162 related articles for article (PubMed ID: 37909139)
1. [Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease].
Liu YC; Zhang Y; Qin SC; Xue JL
Sheng Li Xue Bao; 2023 Oct; 75(5):682-690. PubMed ID: 37909139
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P; de la Torre Aláez M; Sangro B; D'Avola D
J Physiol Biochem; 2023 Nov; 79(4):869-879. PubMed ID: 36976456
[TBL] [Abstract][Full Text] [Related]
3. Covalent Inhibition of Pyruvate Kinase M2 Reprograms Metabolic and Inflammatory Pathways in Hepatic Macrophages against Non-alcoholic Fatty Liver Disease.
Fan N; Zhang X; Zhao W; Zhao J; Luo D; Sun Y; Li D; Zhao C; Wang Y; Zhang H; Rong J
Int J Biol Sci; 2022; 18(14):5260-5275. PubMed ID: 36147457
[TBL] [Abstract][Full Text] [Related]
4. Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease.
Fan N; Zhao J; Zhao W; Zhang X; Song Q; Shen Y; Shum HC; Wang Y; Rong J
J Control Release; 2022 Jul; 347():44-54. PubMed ID: 35483638
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
6. [Effects of celastrol on autophagy and endoplasmic reticulum stress-mediated apoptosis in a mouse model of nonalcoholic fatty liver disease].
Tian T; Liao XC; Zhang M; Wu XM; Guo YT; Tan SY
Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):656-662. PubMed ID: 36038329
[No Abstract] [Full Text] [Related]
7. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.
Zhang Y; Geng C; Liu X; Li M; Gao M; Liu X; Fang F; Chang Y
Mol Metab; 2017 Jan; 6(1):138-147. PubMed ID: 28123944
[TBL] [Abstract][Full Text] [Related]
8. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
[TBL] [Abstract][Full Text] [Related]
9. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
10. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models.
Zhao QY; Ge LH; Zhang K; Chen HF; Zhan XX; Yang Y; Dang QL; Zheng Y; Zhou HB; Lyu JX; Fang HZ
Zool Res; 2020 Sep; 41(5):539-551. PubMed ID: 32786176
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
Kjær MB; George J; Kazankov K; Grønbæk H
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
13. Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.
Zhang N; Tian X; Yan T; Wang H; Zhang D; Lin C; Liu Q; Jiang S
Front Immunol; 2023; 14():1148722. PubMed ID: 37020540
[TBL] [Abstract][Full Text] [Related]
14. Exploring the therapeutic potential of a nano micelle containing a carbon monoxide-releasing molecule for metabolic-associated fatty liver disease by modulating hypoxia-inducible factor-1α.
Cui Y; Guo C; Xia Z; Xue Y; Song B; Hu W; He X; Liang S; Wei Y; Zhang C; Wang H; Xu D; Zhang S; Fang J
Acta Biomater; 2023 Oct; 169():500-516. PubMed ID: 37574157
[TBL] [Abstract][Full Text] [Related]
15. Celastrol functions as an emerging manager of lipid metabolism: Mechanism and therapeutic potential.
Gu J; Shi YN; Zhu N; Li HF; Zhang CJ; Qin L
Biomed Pharmacother; 2023 Aug; 164():114981. PubMed ID: 37285754
[TBL] [Abstract][Full Text] [Related]
16. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
[TBL] [Abstract][Full Text] [Related]
17. The complex function of macrophages and their subpopulations in metabolic injury associated fatty liver disease.
Subramanian P; Chavakis T
J Physiol; 2023 Apr; 601(7):1159-1171. PubMed ID: 36825510
[TBL] [Abstract][Full Text] [Related]
18. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.
Badmus OO; Hillhouse SA; Anderson CD; Hinds TD; Stec DE
Clin Sci (Lond); 2022 Sep; 136(18):1347-1366. PubMed ID: 36148775
[TBL] [Abstract][Full Text] [Related]
20. The microbial metabolome in metabolic-associated fatty liver disease.
Li M; Rajani C; Zheng X; Jia W
J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
